Monitor upcoming FDA End-of-Phase 2 meeting for VCN-01 in PDAC in 1H 2026, which could de-risk the pivotal trial design. The SYN-020 licensing deal de-risks development costs but removes a potential pipeline asset.
Price Chart
Executive Summary
Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tied to VCN-01's Phase 2b trial success, reduced R&D spending, and a licensing deal for SYN-020 that brings $300,000 upfront and up to $38 million in potential milestones. The company has $15.2 million in cash as of February 2026, providing runway into Q1 2027.
Key Financial Metrics
Key Facts
- VCN-01 achieved primary survival and safety endpoints in Phase 2b trial, triggering a $9.0 million contingent consideration expense
- Licensed SYN-020 to Rasayana Therapeutics for $300k upfront, up to $38M in milestones, and tiered single-digit royalties
- R&D expenses decreased 28% YoY to $8.6M due to trial completions
- General and administrative expenses doubled to $15.4M, driven by the contingent consideration adjustment
- Cash balance increased to $15.2M as of February 26, 2026, funding operations into Q1 2027
- Audited financials include a going concern qualification from auditors
Financial Impact
Net loss attributable to common stockholders was $25.2M in 2025 vs $25.7M in 2024; $9.0M non-cash charge from VCN-01 trial success inflated G&A expenses
Risk Factors
- Going concern qualification in audited financials indicates liquidity risk despite current cash runway
- Heavy reliance on successful clinical development of VCN-01 with no near-term revenue prospects
- Market cap of $8M appears disconnected from fundamentals given lack of revenue and ongoing losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254568 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2379 (+3.43%) |
Aug 11, 2026 7w ago | Press Release | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2379 (+3.43%) |
Aug 4, 2026 8w ago | 8-K | $0.2300 $0.2490 | ▼ −8.26% | ▼ −9.50% | $0.2379 (−3.43%) |
Jul 7, 2026 12w ago | 8-K | $0.2354 $0.2227 | ▼ −5.40% | ▼ −6.73% | $0.2379 (+1.06%) |
Jun 11, 2026 16w ago | Press Release | $0.3070 $0.2345 | ▼ −23.62% | ▼ −25.51% | $0.2379 (−22.51%) |
Apr 17, 2026 23w ago | 8-K | $0.4100 $0.3000 | ▼ −26.83% | ▼ −31.03% | $0.2379 (−41.98%) |
Mar 12, 2026 29w ago | 8-K | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2379 (+32.17%) |
Mar 12, 2026 29w ago | Press Release | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2379 (+32.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access